Clinical Trial Update: Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ixabepilone with mitoxantrone plus prednisone in patients with refractory metastatic prostate cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Ixabepilone (ixabepilone)
• Mitoxantrone (mitoxantrone)
• PREDNISONE (Prednisone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED